Today: September 5, 2015, 3:18 am

CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion - new market research report published
CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion - a new market research report on 2014-03-14 08:36:02
With our conservative view on Revlimid - opportunity in EU (no approval in NDMM and Maintenance setting), reimbursement in China, and patent challenges; we expect net product sales´ CAGR (2013-17) of 17% (vs. CELG´s guidance: 19%) including risk adjusted late stage pipeline.

We are positive on upcoming catalysts:

i) Approval of Registered / Late-Stage products - POMALYST (pomalidomide, R, PDUFA: Feb. 10, 2013 and EU in 2H13), Apremilast (PhIII, Psoriasis - PsO, PsA; PhII, RA, oral PDE-4 inhibitor), and label expansion of ABRAXANE (L, mBC);

ii) Upside should come from novel early stage pipeline where more details will be disclosed during the R&D update in May; iii) Growth from label and geographic expansion of Marketed Products - Vidaza (in AML) and Revlimid (in MCL, MDS in EU), where approval in NDMM and Maintenance setting of Revlimid is a wild card.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.